Guinea-Bissau vs Togo: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Guinea-Bissau
90.0%
in 2025
Togo
89.0%
in 2025
Guinea-Bissau rank
70th
Togo rank
72nd
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Guinea-Bissau
- Togo
How they compare
Guinea-Bissau currently reports 90.0% against 89.0% in Togo, a difference of 1.0%.
The two have swapped places 5 times across 18 shared years of data; in 2008 it was Togo ahead.
Guinea-Bissau ranks 70th and Togo ranks 72nd of 194 countries.
Togo has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Guinea-Bissau | Togo | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | — |
| 2010s | 34.1% | 43.9% | 9.8% | Togo |
| 2020s | 85.5% | 89.0% | 3.5% | Togo |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Guinea-Bissau or Togo?
- Guinea-Bissau, at 90.0% against 89.0% in Togo as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Guinea-Bissau and Togo?
- 1.0%, with Guinea-Bissau ahead.
- How many years of comparable data are there for Guinea-Bissau and Togo?
- 18 years are reported by both, from 2008 to 2025.
- How do Guinea-Bissau and Togo rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Guinea-Bissau ranks 70th and Togo ranks 72nd of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.